UroGen Pharma has received the NDA acceptance from the US FDA for UGN-102 (mitomycin) to treat bladder cancer.

The chronic obstructive pulmonary disease (COPD) market in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) is set to grow from sales of $11.5bn in 2023 to $30.8bn in ...

Bayer notches up pressure on rival Astellas’ Veozah with an EU marketing authorisation application for its hot flash relief ...

The agreement will see MEDiC’s MCAT platform identify biomarkers to support the development of Hanmi’s clinical assets.

In pharmaceutical manufacturing, viscous drug products pose unique challenges to filling efficiency and accuracy.

Huawei hosted GITEX's Industrial Digital and Intelligent Transformation Summit and launched joint solutions with partners for ...

Stelara is one of the most successful Crohn’s therapies, generating $10.8bn last year, Lilly hopes to introduce Omvoh as its ...

Despite this setback, Transgene plans to explore the potential benefits of the vaccine in specific patient populations.

Boehringer Ingelheim, in partnership with the WHO Foundation [an organisation set up to support the World Health Organization ...

digital twins can be used to progress healthcare, drug development, and research by enabling the delivery of personalised ...

Pharmaceutical giants cannot work in a silo to reach net zero. Pharma contract manufactures have a duty to engage with the ...

Lundbeck is to acquire Longboard for $2.6bn equity value in a move set to enhance its capabilities within neuro-rare ...